multicenter non-randomized non-blind exploratory clinical trial of safety and efficacy of cidofovir for adenovirus infection after hematopoietic stem cell transplantation

multicenter non-randomized non-blind exploratory clinical trial of safety and efficacy of cidofovir for adenovirus infection after hematopoietic stem cell transplantation - A clinical trial of administration of cidofovir for adenovirus infection after hematopoietic stem cell transplantation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011158

Enrollment

Registered

2013-07-10

Start date

2013-07-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adenovirus infection after hematopoietic stem cell transplantation

Interventions

Cidofovir 1 mg/kg/day is administrated intravenously three times a week for two weeks. Intravenous hydration with normal saline and oral probenecid are required to prevent renal damage.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who have received hematopoietic stem cell transplantation 2. Patients with adenovirus infection 3. Patients with risk to be severe 4. Patients who agree in writing

Exclusion criteria

Exclusion criteria: 1. Allergy to drugs used in this trial 2. Serum creatinine higher than 1.5 mg/dl (In case of renal dysfunction by viral infection, higher than 2.5 mg/dl) 3. History of receiving foscarnet 4. During pregnancy, breastfeeding or potential pregnancy 5. Patients who are recognized as inadaptable for this trial

Design outcomes

Primary

Measure	Time frame
Virological response after treatment	—

Secondary

Measure	Time frame
1) Clinical response of adenovirus infection 2) Adverse events 3) Survival at 2 months after treatment Changes of data below from pre to post-treatment 4) Serum creatinine 5) Proteinuria, urine occult blood 6) Blood cell count 7) Venous blood gas analysis 8) Number of cytomegalovirus antigen positive cell	—

Countries

Japan

Contacts

Public ContactKatsuya Fujimoto

Hokkaido University Graduate School of Medicine Department of Hematology

kfujimo@med.hokudai.ac.jp011-706-7214

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026